Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by BCL2L14 belongs to the BCL2 protein family. Additionally we are shipping BCL2-Like 14 (Apoptosis Facilitator) Proteins (7) and many more products for this protein.
Showing 10 out of 39 products:
Human Polyclonal BCL2L14 Primary Antibody for EIA, IHC (p) - ABIN356813
Benito, Gutierrez, Pipaon, Real, Gachon, Ritchie, Fernandez-Luna: A novel role for proline- and acid-rich basic region leucine zipper (PAR bZIP) proteins in the transcriptional regulation of a BH3-only proapoptotic gene. in The Journal of biological chemistry 2006
Data indicate that LRP6 (show LRP6 Antibodies), BCL2L14, DUSP16 (show DUSP16 Antibodies), CREBL2 (show CREBL2 Antibodies), and CDKN1B (show CDKN1B Antibodies) were involed in centromeric (12p11.21-12p13.2) deletion in ETV6 (show ETV6 Antibodies)-RUNX1 (show RUNX1 Antibodies) B-cell precursor acute lymphoblastic leukemia (BCP (show OPN1SW Antibodies)-ALL).
Single nucleotide polymorphism in BCL2L14 is associated with lung cancer.
prior knockdown of Bcl-G expression ablates the stimulation of basal apoptosis by FAU (show FAU Antibodies), consistent with an essential downstream role for Bcl-G, itself a candidate tumour suppressor, in mediating the apoptosis regulatory role of FAU (show FAU Antibodies).
siRNA downregulation of Bcl-G inhibited breast cancer cell apoptosis. Adding an siRNA against Fau (show FAU Antibodies) revealed control of Bcl-G by Fau (show FAU Antibodies). The most important factors controlling Bcl-G are post-translational modification by Fau (show FAU Antibodies) & MELK (show MELK Antibodies), not transcription rate.
There was no somatic mutation of BH3 domains of Bad, Bmf (show BMF Antibodies) and Bcl-G genes in transitional cell carcinoma samples. The data presented here indicate that BH3 domain mutation of these genes is rare in TCCs and may not contribute to the pathogenesis of TCCs.
the kinase activity of MELK (show MELK Antibodies) is likely to affect mammary carcinogenesis through inhibition of the pro-apoptotic function of Bcl-GL
data presented here indicate that BH3 domain mutation of the proapoptotic genes Bad, Bmf (show BMF Antibodies) and Bcl-G is rare in laryngeal squamous cell carcinoma and may not contribute to the apoptosis-resistance mechanisms of laryngeal squamous cell carcinoma
JAB1 (show COPS5 Antibodies) is involved in the regulation of mitochondrial apoptotic pathway through specific interaction with BclGs.
Increased BclG(L) expression may contribute to the aberrant CD4 (show CD4 Antibodies)+ T cell apoptosis which causes an inappropriate immune response and impaired homeostasis in systemic lupus erythematosus.
CD3 (show CD3E Antibodies)/CD28 (show CD28 Antibodies)-inducible MNSFbeta (show FAU Antibodies)-Bcl-G complex may be involved in the regulation of T cell function and survival.
Bcl-G is expressed highly in mature spermatids in the testis, CD8 (show CD8A Antibodies)(+) conventional dendritic cells (DCs) in hematopoietic tissues and diverse epithelial cell types, including those lining the gastrointestinal and respiratory tracts.
The protein encoded by this gene belongs to the BCL2 protein family. BCL2 family members form hetero- or homodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. Overexpression of this gene has been shown to induce apoptosis in cells. Three alternatively spliced transcript variants encoding two distinct isoforms have been reported for this gene.
apoptosis facilitator Bcl-2-like protein 14
, apoptosis regulator BCL-G